Descriptive Observational Epidemiological Study on the Characteristics of Thyroid Cancer in Patients Treated in Oncology Services of Spanish Centers: National Registry of Thyroid Cancer - Differentiated, Medullary and Anaplastic
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Situation of the tumor at first-diagnosis
研究概览
简要总结
An epidemiological, observational, multicenter, cross-sectional, retrospective study on patients ≥ 18 years visited in the oncology services of the participating centers with diagnosis of primary thyroid cancer.
研究设计
- 研究类型
- Observational
- 观察模型
- Ecologic Or Community
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients older than 18 years with diagnosis of differentiated, medullary or anaplastic thyroid cancer confirmed by histopathology.
- •Patients who agree to participate and are able to understand the information sheet and sign the informed consent
排除标准
- •Patients under 18 years of age.
- •Patients with other types of thyroid cancer or whose histopathological diagnosis has not been confirmed.
- •Patients who do not have the relevant basic information to be included in the study, according to the criteria of the principal investigator.
结局指标
主要结局
Situation of the tumor at first-diagnosis
时间窗: Baseline
Local tumor, locoregional tumor or metastatic disease.
Tumor-Node-Metastasis classification
时间窗: Baseline
Based on the AJCC (American Joint Committee on Cancer) 2018 TNM system: T for extent or size of the tumor, N for lymph nodes spread and M for metastasis.
Tumor Stage
时间窗: Baseline
From I to IV, based on the interpretation of the TNM classification and depending on the hystopathological characteristics of the tumor.
Hystopathological characteristics of the tumor
时间窗: Baseline
Based on pathologist evaluation of biopsy including differentiated, medullar or anaplasic.
次要结局
- Number of patients with P53 mutation(12 months)
- Patient situation at the end of treatment(12 months)
- Number of patients with RAS mutation(12 months)
- Number of patients with BRAF mutation(12 months)
- Number of patients with RET mutation(12 months)
- Number of patients with PI3K mutation(12 months)
- Number of patients with PAX8/PAR mutation(12 months)
- Number of patients with PTEN mutation(12 months)